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1. Introduction
HIV-Associated Neurocognitive Disorders (HAND) is a serious menifestation of HIV in‐
fection in the central nervous system (CNS), and encompassess a wide spectrum of cog‐
nitive,  behavioral,  and  motor  deficits  [1-3].  While  the  implementation  of  combination
antiretroviral  therapy  (ART)  has  dramatically  increased  the  life  expectancy  and  led  to
significant improvements in the clinical presentation and progression of HAND, an esti‐
mated 50% of HIV-infected patientscontinue to suffer from implications of HAND in the
ART era, with as much as 20% of these exhibiting symptoms of HIV-associated dementia
(HAD), the most severe form of HAND [3-6]. The brain regions affected in patients with
HAND has  changed in  the  ART era  in  parallel  to  the  changes  observed in  the  clinical
picture; a more subtle and insidious cortical damage mainly in the hippocampus and the
temporal cortex is observed, in contrast to the overt subcortical damage seen before ART
[7-10]. The underlying causes of these changes are not fully elucidated; however, exami‐
nation of  the post-mortem tissue reveals  the persistence of  synaptic  and dendritic  dam‐
age  in  the  affected  brain  regions  [3,  11].  Emerging  evidence  suggests  that  controlling
viral replication in the periphery or in the CNS may not be sufficient to control the un‐
derlying neuropathological  processes  that  culminate  in  the development  of  HAND. The
impact of HAND on the quality of life,  adherence to drug regimens, and co-morbidities
especially in an aging HIV population with decreased cognitive reserves, is of major con‐
cern. In this chapter, we will examine the major factors that continue to impact the CNS
of HIV-infected individuals, and introduce new challenges in the successful treatment of
HAND.
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2. Clinical presentation and neuropathology of HAND
According to the diagnostic criteria established for the assessment of neurocognitive impair‐
ment in HIV-infected individuals, the neurological deficits in HAND patients are divided
into three diagnostic groups. This classification is based on the neuropsychological evalua‐
tion of multiple cognitive domains, including simple motor skills or sensory perceptual abil‐
ity, complex perceptual motor skills, attention and working memory, learning and memory
recall, verbal and language, abstraction and executive function. Asymptomatic neurocogni‐
tive impairment (ANI) is defined as acquired impairment in at least two cognitive domains
without a decline in activities of daily living (ADL), while mild to moderate neurocognitive
impairment that affects ADL is termed minor neurocognitive disorder (MND). Moderate to
severe impairment in two or more domains with marked impact on ADL is defined as HAD.
Additionally, behavioral and emotional problems such as depression, psychosis and anxiety
are commonly observed in HAND patients. Since the multi-drug regimens that form the ba‐
sis of ART have become the mainstay of HIV, the clinical presentation and the course of
HAND have become more unpredictable. The severity of deficits appears to fluctuate over
time during the course of infection: some patients may experience continuing decline in cog‐
nitive abilities, while others may recover from HAD and exhibit only minor deficits for the
remainder of the disease. While clinical studies clearly establish that suppression of viral
replication below the level of detection is paramount to a more favorable outcome, the clini‐
cal course of HAND, once diagnosed, cannot be predicted successfully in most patients.
While microglial nodules, multinucleated giant cells and astrogliosis, all of which are associ‐
ated with HIV-induced inflammatory changes, are not as frequently found in post-mortem
HAND brain tissue after ART, dendritic and synaptic damage still persist [12-16]. For exam‐
ple, several studies have reported the presence of deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL)-positive cells, DNA laddering and structural changes
with electron microscopy [17, 18]. Importantly, these markers of neuronal death correlate
with activation of immune cell populations suggesting that the inflammatory mediators se‐
creted by these cells may play a role in initiating the death cascades [1, 19]. Given the chron‐
ic nature of the HIV infection in the ART era, co-existing conditions which can activate
immune responses and precipitate a neuroinflammatory environment independent of infec‐
tion are likely to contribute to the development of persistent neuropathology, and need to be
addressed for a more efficient clinical approach and more favorable outcomes. Foremost, it
is necessary to examine the mechanisms of neuronal injury in order to successfully expound
on the contribution of confounding factors on the persistence of HAND.
The two major cell types targeted by HIV are CD4+ T cells and the cells of monocyte/macro‐
phage lineage. HIV infection of the CD4+ T cells ends in the selective loss of this cell popula‐
tion, leading to severe immunodeficiency [20]. More relevant to HAND, HIV also targets
monocytes early during infection [20]. In the healthy brain, the BBB and the blood-cerebro‐
spinal fluid barriers are the first lines of defense against invading pathogens; however, HIV
can circumvent these barriers and enter the CNS within infected monocytes [21, 22]. Accord‐
ing to this model, supported by a multitude of in vitro and in vivo studies, the infected mon‐
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ocytes differentiate into macrophages, and constitute the viral reservoirs in the CNS [23-26].
Moreover, these cells release a variety of molecules, some of them known neurotoxins, lead‐
ing to the eventual neuronal damage and dysfunction observed in HAND. Importantly, un‐
like other cell types that readily undergo replication, neurons in their post-mitotic state are
more vulnerable to immune cell damage which can disrupt critical neuronal functions. Ad‐
ditionally, recent focus in efforts towards a cure in HIV is purging the virus from its reser‐
voirs, by reactivating pro-viral DNA [27-31]. Thus, it is crucial to examine the impact of HIV
infection on immune cells for a better understanding of the neuropathology of HAND, and
for the development of successful paradigms for HIV reactivation and purging.
3. The immunology of HAND
3.1. Initiation of immune response in the CNS
HIV initially enters helper T lymphocytes and monocytes in the periphery via viral glyco‐
proteins, gp120 and gp41, which are part of the HIV envelope [32]. These glycoproteins en‐
gage with the CD4 on the host cell membrane; however, this fusion step requires the
presence of a chemokine co-receptor, C-X-C chemokine receptor type 4 (CXCR4) in lympho‐
cytes,orC-C chemokine type 5 (CCR5) / C-C chemokine type 3 (CCR3) in macrophages [32,
33]. Of all the cell types in the brain, only macrophages and microglia express CD4 antigen,
are commonly infected by HIV, and are capable of productive infection. There is very limit‐
ed evidence for HIV infection of the glial cells, which if present, has not been conclusively
shown as being productive [34]. More importantly, HIV cannot infect neurons as these cells
lack CD4 co-receptors.
The CNS of a healthy adult human has a relatively low presence of cellular components
of the immune system [35, 36]. The CNS presents the immune system with unique prob‐
lems  with  trafficking  of  immune  cells  and  the  recognition  of  foreign  antigen  when
present. First, the BBB constitutes a physical barrier for the entry of cells and macromole‐
cules from the periphery into the CNS. Additionally, there is minimal expression of major
histocompatibility class II  (MHC class II)  molecules and an absence of professional anti‐
gen presenting cells such as dendritic cells, all of which are required for antigen presenta‐
tion and adaptive immune response activation. However,  it  has been extensively shown
that brain derived factors act to suppress or counter-regulate the actions of pro-inflamma‐
tory  mediators  in  the  CNS  where  immune  surveillance  is  not  sufficient.  For  example,
transforming growth factor-β  (TGF-β)  has  the  ability  to  inhibit  the  activation of  macro‐
phages, T lymphocytes, and natural killer (NK) cells, and has been shown to possess neu‐
roprotective capabilities [37-41]. Interestingly, increased TGF-β protein levels are reported
in the frontal cortex of HAD patients, and elevated TGF-βimmunoreactivity has been de‐
tected in  reactive  astrocytes  and mononuclear  cells  of  the  white  matter  in  HIV-infected
CNS [42, 43]. Similar roles have been proposed for BDNF, NT-3, and NGF, among others,
during HIV infection in the CNS [44, 45].
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In the initial stages of HIV infection, the number of CD4+T cells decreases as a consequence
of uncontrolled viral replication. While the impact of primary HIV infection on specific CD8+
T cell subpopulations is not clear, there is an overall expansion of this cell population [46]. In
this environment, infected monocytes can enter the CNS, establish and maintain productive
infection, and HAND becomes clinically manifest. Perivascular macrophages are replenish‐
ed throughout life by the migration of circulating monocytes to the brain, a process en‐
hanced in an inflammatory environment [47]. Several studies have shown that the number
of activated macrophages, rather than the viral load,correlates best with the axonal damage
and synaptic loss observed in the HAND brain [11, 14, 48, 49]. In addition, indirect markers
of macrophage activation, such as neopterin and β2-microglobulin, are elevated in the CSF
of HAND patients [50-52]. Further, soluble factors that are known to be released by macro‐
phages and glia, such as quinolinic acid, tumor necrosis factor-α (TNF-α), reactive oxygen
species (ROS), and cytokines such as CXCL12 (stromal cell-derived factor-1, SDF-1), CCL2
(monocyte chemotactic protein-1, MCP-1), and interleukin-6 (IL-6), are also elevated in the
CSF of HAND patients [53-57]. These findings reinforce the model which proposes mono‐
cyte-derived macrophages and microglia as major instigators of the neuropathological proc‐
esses in the course of disease development in HAND.
It should be noted that viral proteins such as gp120 and transactivator of transcription (Tat)
can directly activate uninfected macrophages [58-62]. Additionally, one mechanism of injury
that is proposed to account for neuronal damage in the absence of neuronal infection by
HIV involves direct neurotoxicity by these viral proteins. Several in vitro studies have shown
that these viral proteins that are released and/or shed by the infected macrophages/micro‐
glia can induce direct synaptic and neuronal damage [63-65]. However, the indicators of
neuroinflammation continue to persist despite successful suppression of replication in the
CSF to levels below the limit of detection with ART, suggesting that other, less direct mecha‐
nisms of injury might be major contributors to the underlying neuropathology.
3.2. The role of cytokines and chemokines in HAND neuropathology
A number of indirect mechanisms for the pathogenesis of HAND have been proposed [1, 25,
66]. These mechanisms are not mutually exclusive, and may be synergistic based on the
common background of macrophage activation and release of cytokines and chemokines.As
a protective measure to suppress viral production, macrophages are responsible for the pro‐
duction of inflammatory mediators including TNF-α, IL (interleukin)-1, interferon-α (IFN-α)
and nitric oxide synthase (NOS) [33, 59]. However, the release of these pro-inflammatory cy‐
tokines can activate the uninfected macrophages, and can induce the migration of leuko‐
cytes into the CNS [62]. For example, in HIV-1 transgenic (Tg) rats, elevated levels of IL-1β
and TNF-α and increased expression of arachidonic acid cascade enzymes have been impli‐
cated in neuronal damage and cognitive and behavioral impairment [67]. A recent study in‐
dicates that similar changes could contribute to cognitive impairment in HIV-infected
patients despite an effective ART [68]. In vivo studies suggest that the progression of HAND
may be predicted by high concentrations of TNF-α in plasma, and polymorphisms in the
TNF-α promoter are associated with HAND to a degree [69, 70]. Interestingly, functional ex-
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vivo studies have shown that the macrophages and B-lymphocytes isolated from HIV-infect‐
ed patients are activated despite viral suppression by ART [71]. Further, in vitro experiments
show that HIV reactivation can be achieved by cytokine and chemokine stimulation [30, 33].
These findings are especially important in light of recent concerns regarding viral latency
and its contribution to the persistence of HAND [29].
In the CNS,chemoattractant cytokines, or chemokines have been demonstrated as essential
factors in neuroinflammation and related neuronal injury and loss through their regulation
of inflammatory responses. Post-mortem studies have revealed up-regulation of chemokines
and chemokine receptors in the brains of patients with HAND [25, 26, 56, 72-75]. The best-
characterized chemokines up-regulated in HAND are the β-chemokines CCL2, CCL5, and
CX3CL1, and the alpha chemokine CXCL12. For example, the levels of one of the more po‐
tent chemokines, CCL2 correlate with the likelihood and severity of HAND [76, 77]. In addi‐
tion, an intriguing regulatory role for the chemokine CCR5 was demonstrated that its
activation led to cell death via caspase-3 mediated apoptosis in a neuroblastoma cell line
[78]. Further, induction of apoptosis has also been reported with CXCL12 in primary neuro‐
glial cultures in the absence of the HIV viral protein gp120. However, results from several
recent studies suggest that the changes in the expression of these chemokines may indicate
neuroprotective efforts in response to the neuroinflammatory environment [79]. Further
studies are needed to dissect the roles of chemokines in HAND pathogenesis, as they take
part in a crucial phase in immune responses, and provide attractive targets for modulation
in resolving HAND persistence.
The mechanisms by which the neuroinflammatory environment eventually ends in damage
to the neurons are not precisely known; however, several mechanisms are likely candidates.
Studies suggest that the neuronal damageis a result of indirect effects of viral proteins as
well as inflammatory mediators [1, 66]. Gp120 and Tat are reported to induce neuronal
apoptosis by activating death-associated proteases, caspases, specifically caspase-3 in in vitro
and in vivo disease models [80]. Another mechanism proposes a role for excitotoxicity secon‐
dary to impaired glutamate reuptake by astrocytes which are overwhelmed by pro-inflam‐
matory factors [81]. The well-defined cascade of excitotoxic injury includes excess Ca2+
influx into the neuronal cytoplasm. Several downstream events secondary to such increases
in Ca2+ such as excess free radical production and oxidative stress, and the activation of Ca2+-
dependent death proteases, calpains and caspases, will be detrimental to neurons, especially
in an environment with inadequate glial support and ongoing inflammation due to immune
cell activation [1, 66].
3.3. Neuroinflammation in HAND
The persistence of immune activation in the CNS and the peripheral nervous system (PNS)
of HIV-infected individuals in the ART era is supported by several lines of evidence. The
relatively low levels of HIV RNA in the presence of widespread neuropathological changes
in the CNS and PNS of HAND patients, and the lack of evidence of HIV infection of neuro‐
nal cells in vivo and in vitro hint at the possibility of chronic immune activation as a factor in
the persistence of HAND. Recent clinical evidence shows that ART reduces intrathecal im‐
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munoactivation in treated patients; however, a significant percentage of patients continue to
exhibit signs of ongoing inflammation [49, 50, 82, 83]. Further, even after successful reduc‐
tion of HIV RNA levels below the limit of detection for several years, patients present with
increased levels of inflammatory markers such as CSF neopterin and intrathecal IgG [52]. It
is thus apparent that ART is not sufficient to prevent or control HAND. One major factor to
consider in addressing this failure is that ART may not be efficient and/or sufficient in con‐
trolling the inflammatory cascade triggered by HIV infection.
Once HIV replication is established in the CNS, the initial chemotactic and inflammatory
factor production leads to further recruitment and activation of monocytes/macrophages,
creating a perpetual neuroinflammatory environment. The phenomenon of monocyte/
macrophage recruitment can be explained by a “push and pull” mechanism [47]. Two key
chemokines that play a role in the recruitment, or “pull”, of monocytes are CCL2 and frac‐
talkine (CXCL1).CCL2 is considered to be the more critical factor involved in the infiltration
of monocytes and lymphocytes across the BBB in the HAND brain [79]. Multiple cell types
of the CNS have been shown to produce CCL2 in models of inflammation, in which CCL2 is
a part of a signaling mechanism for recruitment of monocytes/macrophages from the pe‐
riphery. For example, leukocyte infiltration into the brain parenchyma has been demonstrat‐
ed upon pertussis toxin challenge in CCL2 transgenic mice [84]. More importantly, HIV-
infected leukocyte transmigration across BBB is dependent on CCL2 in an in vitro model of
disease [85]. Further, CCL2 has been shown to directly damage the endothelial cell junctions
of the BBB [86]. These findings clearly indicate a significant role for CCL2 in the “pull” of
monocyte/macrophages across the BBB in HAND. Interestingly, CCL2 levels remain elevat‐
ed in the CSF of HAND patients on ART, implicating that ongoing trafficking might be oc‐
curring despite viral suppression, and warrants further investigations into the persistence of
HAND in the era of ART [83].
The “push” aspect of the monocyte/macrophage recruitment involves the expansion in pe‐
ripheral blood neuroinvasive monocyte population. It has been shown that individuals with
HAND exhibit an expanded population of CD14+ peripheral blood monocytes that co-ex‐
press CD16, which is considered a more mature population [21]. These CD14+/CD16+ mono‐
cytes are preferentially susceptible to infection, and can serve as a reservoir harboring pro-
viral DNA. The entry of monocytes into the brain plays a key role in initiating the series of
events that lead to HAND, and although antiretrovirals hinder viral replication, they may
have minimal effects on the continued transmigration of monocytes into the brain. One
study showed that a single exposure of the CNS to the neurotoxic viral protein Tat led to the
infiltration of peripheral blood monocytes and resulted in prolonged disruption of CNS
function [87]. Thus, continuous and efficient viral suppression in the periphery is critical in
achieving suppressed inflammation in the CNS, and is of prime importance in the fight
against HAND.
While macrophages and microglia play primary roles in HIV infection in the CNS, other
glial cells also contribute to the neuroinflammation and neurotoxicity in the HAND brain.
One important cell type that needs to be mentioned in the neuroinflamatory processes in
HAND is the astrocytic cell population. As the most abundant cells in the CNS, astrocytes
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provide neurotrophic support, and are involved in repair processes for neurons. Further, as‐
trocytes are physiological regulators of microglial and macrophage inflammatory responses,
and indirectly modulate neuronal survival through reduction of the macrophage inflamma‐
tory response. However, their dysfunction, as a result of HIV infection, will lead to the dys‐
regulation of the local cytokine/chemokine balance. Evidence has shown that astrocytes are
key mediators in the regulation of microglial function and its influence on the onset and the
progression of HAND [55, 88]. Viral proteins gp120, and Tat both activate astrocytes to pro‐
duce pro-inflammatory cytokines TNF-α, IL-6, and IL-1β as well as the pro-inflammatory
chemokines CCL2 and CXCL10 [34, 55, 89-91]. The contribution of these pro-inflammatory
mediators by astrocytes as well as the release of pro-inflammatory cytokines IL-1β and TNF-
α by microglia and macrophage will only exacerbate the inflammatory environment in the
HIV-infected CNS.
Although the pathogenic mechanisms of HAND are likely to be multifactorial (Table 1), cel‐
lular activation with the initiation and persistence of the immune system in the CNS play a
pivotal role in this disease progression. Continued CNS inflammation is an essential factor
in many neurodegenerative diseases and HIV infection induces a cascade of inappropriate
immune responses in the CNS. The initial immunological response has protective intentions
through macrophage activation, but with persistent infection, the inflammatory response be‐
comes toxic to the neurons through the production of pro-inflammatory cytokines and che‐
mokines. Further, the decreased viral load in the CNS is accompanied by persistent
microglial activation and inflammation. Ineffective drug penetrance into the CNS, which
continues to be a challenge, can initiate the development of resistance to ART via permitting
mutations to the virus which allows the CNS to become a reservoir for the infection. As
HIV-infected macrophages are shown to be resistant to apoptosis,this will end in exacerbat‐
ing the virus reservoir in the CNS.
Inflammatory Responses During HIV-1 Brain Infection
Macrophage Activation (M1 phenotype)
Micogial nodules
Multinucleated Giant Cells in Central White Matter and Deep Gray Matter
Astrogliosis
Cytokines
Transforming Growth Factor-beta (TGF-β)
Tumor Necrosis Factor-alpha(TNF-α)
Interleukin-6 (IL-6)
Interleukin-1 (IL-1)
Chemokines
Monocyte Chemotactic Protein-1 (MCP-1)
Interferon Gamma Induced Protein-10 (IP-10)
MHC class II presentation
Table 1. Pathological and laboratory evidence for immune activation in the CNS after HIV infection.
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It should also be noted that the impact of HIV infection in the peripheral tissue will ulti‐
mately impact the immune responses in the CNS. Thus, co-morbidities such as co-infections,
substance abuse, malignancies and antiretroviral drug toxicities, as well as general inflam‐
matory processes in the periphery, such as oxidative stress should be taken into account
when assessing the relationships between immune responses and the neuropathological
processes occurring in the HAND brain. This approach will provide more efficient tools,
and will have a greater impact on resolving the persistence of HAND.
4. Oxidative stress in neurodegenerative diseases
Oxidative stress is a shared pathological finding in a myriad of neurodegenerative diseases
including Alzheimer Disease, Parkinson Disease, Multiple Sclerosis (MS), Amyotrophic Lat‐
eral Sclerosis (ALS), and HAND [92, 93]. While it is clear that chronic oxidative stress which
will overwhelm the protective capacities of the cellular endogenous antioxidant responses
may be responsible in part for the neuronal death occurring in these conditions, in many
neurodegenerative diseases it is difficult to ascertain whether oxidative stress is the causa‐
tive factor for disease pathology and progression, or rather a resultant downstream event of
other cellular dysfunctions [92-95]. Nonetheless, in HAND, several lines of evidence suggest
that both HIV and antiretroviral compounds may result in oxidative and nitrosative stress in
the periphery and in the CNS [96-102]. Deficits in total antioxidant levels and increases in
the markers for oxidative stress are still observed in individuals on stable ART regimens
with undetectable viral titers, necessitating the need for adjunctive therapies to ameliorate
this imbalance [103, 104]. As has been suggested in a variety of neurodegenerative condi‐
tions, antioxidant supplementation or upregulation of the endogenous antioxidant response
in cells of the CNS may ameliorate the neuronal damage and death in HAND [1, 93, 94, 105].
4.1. Oxidative stress in the era of ART
The evidence of disrupted antioxidant balance and oxidative stress represent a continued
concern for HIV-infected individuals even when virus is successfully controlled by ART
[102]. To understand the magnitude and implications of this problem, it is important to un‐
derstand the initial disruptions to the antioxidant system that were observed in infected in‐
dividuals, and determine whether ART contributed to the resolution or the exacerbation of
these problems.
Oxidative stress prior to ART:As early as 1988, while researchers were just beginning to un‐
derstand the HIV virus, Sönnerborg and colleagues determined that plasma levels of malon‐
dialdehyde in adults with HIV infection were elevated up to 30% when compared with
controls [106]. Malondialdehyde is the breakdown product of polyunsaturated lipids by re‐
active oxygen species, and is a mainstay in terms of a biological marker for measuring the
relative levels of lipid peroxidation and oxidative stress in individuals [107]. A multitude of
studies followed, showing significant increases in the levels of free radicals, hydroperoxides,
hydroxynoneal, and oxidation of thiols in infected individuals, and confirming that malon‐
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dialdehyde is increased significantly in infected adults, as well as children [108-118]. The
metabolic synthesis of lipids is closely tied to the oxidative state of the cell and the lipids
residing in the cell membrane, as certain enzymes such as sphingomyelinase, are sensitive to
the oxidative status of the cell and regulate their activity based on cellular need [119]. Stud‐
ies looking into the production of sphingolipids illustrated an overproduction of both sphin‐
gomyelin and ceramides with HIV-infection, suggesting a lipid imbalance caused by the
virus [115, 116, 119]. Additionally, studies showed remarkable deficiencies in antioxidant
micronutrients including zinc, selenium, Vitamin C, Vitamin D, Vitamin E and beta-carotene
(Vitamin A) [109, 110, 118, 120-126]. Conflicting reports exist on perturbation of total antioxi‐
dant status prior to ART, with severalclinical studies reporting decreased total antioxidant
capacity [108, 113, 118], while Repetto et al. described an increase in the overall antioxidant
capacity as individuals progressed to AIDS [114]. The discrepancies between these findings
are likely based on the assays utilized to determine “total antioxidant capacity”, as different
enzymatic approaches target different portions of the antioxidant system.
Activity levels of superoxide dismutase (SOD), which catalyzes the detoxification of the oxi‐
dant superoxide into hydrogen peroxide and water, were assessed by a variety of laborato‐
ries. Elevated SOD activity was observed in all evaluated HIV-infected individuals, with
further increases occuringwith disease progression to AIDS. In addition, increases in SOD
mRNA levels were reported in individuals with HAD, as compared to those who were neu‐
rocognitively normal [114, 127, 128]. These changes in SOD were observed in microglial
cells, as well as in HIV-infected macrophages, suggesting a virus-triggered induction [128].
An essential antioxidant found in the brain which buffers many reactive oxygen species is
glutathione. In HIV-infected patients, overall glutathione levels were found to be reduced,
and the remaining glutathione was greatly skewed to the oxidized versus reduced form.
[114, 127, 129, 130]. The enzyme glutathione peroxidase, which promotes the conversion of
hydrogen peroxide to water through the use of glutathione, was also decreased, illustrating
a severe imbalance in this system whose goal is to maintain cellular redox homeostasis [121].
Another deleterioius consequence of rampant pro-oxidants within cells is oxidative modifi‐
cation of DNA bases. Increased levels of 5-hydroxyuracil, 5-hydroxycytosine, 8-hydroxyade‐
nine and 8-hydroxyguanine were found when comparing DNA isolated from lymphocytes
of HIV-infected individuals versus uninfected controls [131]. One other common product of
an imbalanced oxidative state which is beginning to gain more interest and research focus is
peroxynitrite. This compound, which is formed when superoxide reacts with nitric oxide, is
detectable through its nitrotyrosine moiety, and is found at higher levels and with more fre‐
quency in the brains of patients with HAD, compared with those who are neurocognitively
normal [128]. In addition to the generation of superoxide as a direct result of HIV infection,
the virus also increases mRNA expression of inducible nitric oxide synthase (iNOS), which
enables a precipitous accumulation of this deleterious oxidation product [128].Further re‐
search in the Nath laboratory has illustrated that thirteen proteins with nitrotyrosine modifi‐
cations are present in the CSF of individuals with HIV-infection. Individuals with dementia
had the highest levels of these nitrites and nitrates. Importantly, three of these proteins were
significantly elevated in individuals who showed declines in neurocognitive assessment
over a period of 6 months [101].
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While it appears that there is not an all-or-nothing increase or decrease in antioxidant ca‐
pacity, the evidence is clear that the components of the antioxidant defense system prior
to ART were greatly affected by HIV-infection, and that the capabilities of endogenous an‐
tioxidant  response were  not  able  to  alleviate  damaging oxidative  alterations  to  proteins
and DNA.
Persistence of oxidative stress in the era of ART: In the ART era, oxidative stress is still per‐
vasive in individuals living with well controlled HIV-infection [102]. In 2007, a group at the
University of Pennsylvania sought to ascertain whether ART had an effect on inflammation
and oxidative stress in the brains of HIV-infected individuals through utilization of chemi‐
cal-shift magnetic resonance spectroscopy. Through careful analysis of lipid, lactate, and
creatine levels, they determined that the inflammation and oxidative stress initiated by the
HIV infection was not ameliorated in ART-treated individuals, compared to seronegative
controls [132]. While these effects were observed in all HAND patients, the levels of oxida‐
tive stress markers were higher in those with more severe cognitive deficits [132].
Lipid peroxidation is still rampant despite effective viral control. While a couple of studies
report decreased levels in markers of lipid peroxidation in ART-medicated patients, as com‐
pared with those not receiving ART, multiple studies have shown persistent statistically sig‐
nificant increases in hydroperoxides, isoprostanes, and malondialdehyde in ART-treated
HIV-infected individuals, compared to seronegative controls [103, 113, 133-139]. Interesting‐
ly, two independent groups have determined in patient blood samples that the levels of per‐
oxide species and oxidative stress are higher in patients on protease inhibitor (PI) based
regimens, as compared with those in individuals on non-nucleoside reverse transcriptase in‐
hibitor (NNRTI) based regimens, implicating a role for the protease inhibitor class in induc‐
tion or exacerbation of oxidative stress [138, 140].
Micronutrient deficiencies are still problematic with ART, and while most patients have ade‐
quate plasma concentrations of vitamins C, D, and E, reported levels are still considered
sub-optimal and lower than seronegative patients [123, 141]. While subsequent reports have
indicated that zinc and selenium deficits are no longer observed in individuals on ART, fur‐
ther definitive confirmation of these findings is necessary [142, 143]. Additionally, in studies
which evaluated the serum of adults and the saliva of children, the total antioxidant status
was found to be decreased in ART treated HIV-patients when compared to HIV-negative
controls, mirroring findings in studies conducted in the pre-ART era [104, 144].
While several studies have indicated that introduction of ART has been accompanied by an
improvement in overall glutathione status, this effect is not totally rectified and imbalances
still occur [129]. In particular, numerous groups have shown that circulating glutathione lev‐
els are still markedly reduced in HIV-infected individuals, when compared with age-match‐
ed controls, with the ratio of oxidized to reduced glutathione remaining out of balance [112,
133-135, 145]. Unfortunately, studies investigating nitrosative stress and nitrosylated pro‐
teins in HIV-infected individuals on ART are still lacking; however, the Nath, Hammond,
and Sutliff laboratories have been investigating nitrosative stress in HIV, and it is likely that
such reports are forthcoming.
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It has been reported that HIV-positive individuals do not have altered levels of 8-hy‐
droxy-2’-deoxyguanosine [8-oxoG) in their urine regardless of ART or lipodystrophy status
[146]. While these findings appear to be promising, in a very recent study, autopsy tissue
from frontal cortex was stained for both nuclear and mitochondrial 8-oxoG. The levels of
this oxidized DNA product were significantly increased in cases of HAND, suggesting that
ART, or ART in combination with ongoing infection may promote DNA oxidative modifica‐
tion, cellular dysfunction damage and death [147]. Additionally, the presence of clastogenic
factors, which cause chromosomal breaks and DNA damage and which may be released
from cells under conditions of oxidative stress, was observed in the plasma of all HIV-pa‐
tients tested by Edeas et al. [148]. This was true ofpatients that were both asymptomatic and
symptomatic for AIDS-defining pathologies, and was independent of ART status [148]. The
effects of these clastogenic factors appear to persist in multiple cell populations implicated
in HAND pathogenesis. For example, in leukocytes obtained from HIV-infected individuals,
the percentage of cells exhibiting DNA fragmentation was increased in individuals on ART,
as compared with those who were ART- naïve [135]. However, the results of this study have
not addressed the possible contribution of latent or low level of infection to the findings.
Due to pervasive oxidative damage and antioxidant imbalance despite effective long-term
viral control in patients, it is now imperative to recognize the direct effect that viral enclaves
and antiretroviral drugs themselves may have on perpetuating these effects. Further studies
are needed to investigate the independent effects of ART and the virus on oxidative damage
in the CNS, as well as in the periphery in order to better determine therapeutic interventions
to resolve these dysfunctions.
4.2. Oxidative stress induction by HIV
Exhaustive research has been conducted in order to determine the effects of the HIV on in‐
fected cells and the cytotoxic factors released from these cells. As addressed earlier, it is now
clear that HIV-infected macrophages secrete a variety of neurotoxic substances including
glutamate, nitric oxide, and superoxide [96]. Within actively infected human myeloid-mono‐
cytic cell lines or monocyte-derived macrophages, HIV induces an increase in superoxide
anions, with a concomitant increase in superoxide to combat these factors [128, 149]. Mollace
and colleagues have demonstrated that the supernatants from HIV-infected human primary
macrophages induced oxidative stress in astrocytes, as indicated by increases in malondial‐
deyde levels [150]. They further showed that these supernatants, which contained excess su‐
peroxide, induced astrocytic apoptosis, confirming HIV-mediated toxicity of this secreted
product [150]. In a similar fashion, in HIV-infected monocytes, an induction of nitric oxide
synthase and subsequent increase nitric oxide was observed [151]. It is also interesting to
note that elevated oxidative stress in the form of intracellular singlet oxygen is capable of
reactivating latent HIV through long terminal repeat (LTR) transactivation in infected mon‐
ocytes or lymphocytes, suggesting that the virus may rely on oxidative stress signaling cas‐
cades for continuation of long-term infection or viral rebound [152].
The amino acid and neurotransmitter glutamate is normally secreted from neurons into the
synaptic cleft, and is quickly removed and recycled through the actions of astrocytes. This
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molecule normally activates the N-methyl D-aspartate (NMDA) receptor on neurons, and
allows for Ca2+ entry into the cell. However, it has been clearly demonstrated that excessive
extracellular levels of glutamate resulting from overstimulation of neurons, impaired reup‐
take by astrocytes, or release from other cell populations within the brain can lead to hyper‐
activation of NMDA channels, subsequent increases in Ca2+ levels in the neuronal
cytoplasm, resulting in excitotoxic neuronal death [153]. In 2001, Jiang et al. demonstrated
through a series of elegant experiments that the molecule responsible for the neurotoxicity
observed on neuronal cultures was a molecule of less than 3,000 kilodaltons, was not sensi‐
tive to trypsin digestion, and that its neurotoxic effect was blocked by a selective NMDA re‐
ceptor antagonist, MK-801. It was through this study, as well as a subsequent study by
O’Donnell et al. that the increased levels of extracellular glutamate secreted by HIV-infected
macrophages may be a major factor in HIV-infected macrophage mediated indirect neuronal
death [154]. The increases in extracellular glutamate appears to be an effect of dysregulation
of the glutamate synthesis pathway, as inhibition of the mitochondrial glutaminase enzyme
blocks the production and the secretion of glutamate from HIV-infected macrophages
[155-157]. As was distinctly noted in human patient samples, a marked deficiency of gluta‐
thione and an imbalance between the oxidized and the reduced glutathione was observed.
Within cells, glutaminase is the enzyme which converts glutamine to glutamate. It is tempt‐
ing to consider that the oxidative stress resulting from the lack of the antioxidant properties
of glutamine may be very tightly coupled to a depletion of glutamine from cells by hyperac‐
tivation of glutaminase enzymes, precipitating an overproduction of glutamate and trigger‐
ing an excitotoxic neuronal death pathway.
Similar to effects of whole virus in vivo, when gp120 and Tat were injected into the brains of
rats, both of these viral proteins induced lipid peroxidation and glutathione depletion [158].
Additionally, both of these proteins significantly reduced intracellular glutathione, and in‐
creased malondialdehyde in immortalized brain endothelial cells, showing that the oxida‐
tive status of these cells would also be directly affected by the presence of virus. This is of
particular importance as the altered oxidative status of these endothelial cells comprising
the BBB will have potential impact on not only the integrity of the BBB, but also on the mon‐
ocyte/macrophage transmigration to the CNS, an important factor in the persistence of
HAND [159]. Further, when applied to neurons in culture, gp120 and Tat induce disrup‐
tions in the lipid metabolism, leading to increased levels of sphingomyelin, ceramide, and
hydroxynoneal,paralleling disruptions in these pathways observed in the neurons of HAND
patients [116].
Studies that investigated gp120 separately have revealed that it is capable of inducing ROS
formation, and activating the antioxidant response in astrocytes [91, 160]. Studies looking in‐
to the production of oxidant species by gp120 have shown that superoxide ions as well as
nitric oxide are involved in neuronal toxicity [100, 161]. Mechanistically, gp120-induced ni‐
tric oxide formation is dependent on a mannose-specific endocytic lectin in macrophages,
while gp120-induced expression and upregulation of iNOS selectively occurs in astrocytes
in human fetal neuroglial cultures [100, 162]. Multiple studies have shown that in neurons
undergoing gp120-induced toxicity, a significant increase in intracellular Ca2+, likely re‐
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leased from intracellular stores,preceeded death, suggesting at a mechanism of activation of
calpains or other pro-death cellular machinery [63, 160].
Studies investigating Tat-induced neuronal death have revealed that this viral protein trig‐
gered the accumulation of ROS when exogenously applied to a variety of cell  types,  in‐
cluding  lymphocytes,  microglia,  brain  microvascular  endothelial  cells  (BMECs)  and
neurons,  as  well  as  in  HeLa  cells  expressing  Tat  [163-166].  When  directly  injected  into
striatum of rats,  Tat produced dramatic increases in protein oxidative modifications and
protein carbonyls [167]. Protein carbonyls were also markedly increased in HeLa cells ex‐
pressing  Tat,  supporting  in  vivo  data  [166].  In  addition,  decreased levels  of  glutathione
were observed in cardiac myocytes and BMECs exposed to recombinant Tat protein, Tat-
expressing transgenic mice, and in Tat-expressing HeLa cells [164, 168-170].  Two studies
pinpointed the involvement of manganese-dependent superoxide dismutase (Mn-SOD) as
a key player in Tat- induced cellular changes. By expressing Tat in HeLa cells, the labora‐
tories  of  Lehman and McCord convincingly showed that  Tat  suppressed the RNA, pro‐
tein, and activity levels of Mn-SOD, while inducing no changes in the Cu,Zn SOD enzyme
levels  [166,  170].  In  HIV-infected  individuals,  plasma  levels  of  SOD  were  increased  in
plasma, and these changes were in parallel  with disease progression to AIDS. If  the re‐
sults from these HeLa cell studies can be expanded to other cell populations, it is tempt‐
ing  to  speculate  that  perhaps  this  overall  increase  in  SOD  activity  is  a  compensatory
mechanism resulting from the Tat-induced alterations in Mn-SOD activity and the subse‐
quent increases in superoxide ions that cannot be eliminated. The overexpression of Tat in
HeLa  cells  also  led  to  decreases  in  overall  glutathione  levels,  with  a  lower  ratio  of  re‐
duced to oxidized glutathione in the remaining supply, mimicking the effect seen in HIV-
infected individuals in vivo and in HIV-infected macrophages in vitro [166, 170].
Finally, studies focusing on microglia have shown that the expression of HIV viral protein R
(Vpr) can induce oxidative stress pathways, and can activate HIV latent gene expression
[171]. When exogenously applied to human fetal astrocytes, the oxidative stress caused by
Vpr causes decreases in intracellular ATP and glutathione, and skews remaining glutathione
in favor of the oxidized versus reduced form [172].
In summary, exhaustive in vivo and in vitro studies indicate that HIV viral proteins them‐
selves can induce, precipitate and augment oxidative stress in multiple cell types, of both
peripheral and CNS tissue. These findings further emphasize the importance of complete in‐
hibition of viral replication in alleviating oxidative stress via antiretroviral therapy. Howev‐
er, emerging evidence suggests that antiretroviral drugs themselves might inadvertently
lead to oxidative stress.
4.3. Oxidative stress and ART
Due to the requirement for lifelong adherence to antiretroviral regimens to prevent viremia
and immune system compromise, it is necessary to investigate the effects of these com‐
pounds in a cellular context. Many of these drugs are associated with negative side effects,
and have been linked to the metabolic syndrome, atherosclerosis, lipodystrophy, protea‐
some inhibition and the unfolded protein response [173-175]. Additionally, it has become
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apparent that these compounds themselves produce oxidative stress, even in the absence of
virus, and may in fact be contributing to the persistence of oxidative stress in patients with
well controlled viral load [97, 102].
HIV is highly susceptible to mutations, mostly due to the error-prone reverse transcription
step during replication, and underlies the emergence of drug resistant mutations over time
in patients treated with single antiretroviral drugs in the early 1990s. Additionally, the de‐
velopment of more sensitive methods for HIV RNA detection revealed the presence of viral
reservoirs in multiple tissues, including the CNS. These findings led to the revision of antire‐
troviral therapy, which, until that time included mostly single antiretroviral drug regimens.
A multiple drug treatment approach, termed ART, was implemented to aim at different
steps in the HIV replication. Currently recommended ART regimens include a cocktail of
nucleoside/nucleotide reverse-transcriptaseinhibitors (NRTIs/NtRTIs), non-nucleoside re‐
verse-transcriptase inhibitors (nNRTIs), protease inhibitors (PIs), and to a lesser extent, entry
inhibitors and integrase inhibitors(Panel on Antiretroviral Guidelines for Adults and Ado‐
lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adoles‐
cents.Department of Health and Human Services.Available at http://aidsinfo.nih.gov/
contentfiles/lvguidelines/AdultandAdolescentGL.pdf). This approach has led to improved
immune function, long-term viral suppression; and underlies the reductions in HIV-associ‐
ated morbidity and mortality in the era of ART. The recently updated guidelines recom‐
mend ART initiation to all HIV- infected, ART-naive individuals irrespective of CD4+ counts
and the impact of early initiation of ART on HIV-associated neurological complications re‐
main to be seen. While a concensus has been reached regarding the time to initiate ART
based on CD4 cell counts, AIDS-defining illnesses, and certain co-morbidity factors; the pan‐
el did not clearly outline strategies to best eradicate the viral reservoirs in the CNS, and to
decrease the risk of developing HAND among infected patients.
In  the  meantime,  one  major  approach  to  better  control  HAND  has  been  to  implement
therapies that include drugs which achieve therapeutic concentrations in the CNS. While
HIV can circumvent the BBB barrier,  complex drug transport  and efflux mechanisms at
this junction hampers effective antiretroviral concentrations in the brain parenchyma. Re‐
cent efforts to address this hurdle have led to the establishment of CNS penetrance effec‐
tiveness  (CPE)  score,  an  algorithm  based  on  the  chemical  structure,  pharmacodynamic
and pharmacokinetic data of antiretroviral drugs [176-178]. In summary, an antiretroviral
drug with high CPE score is small in size (molecular mass below 400-500 kDa), has high
lipid solubility and low protein binding, and it is not a substrate for drug transport or ef‐
flux proteins. Unfortunately, results of several clinical studies which incorporated CPE in‐
to  the  design  and  the  analysis  of  outcomes  are  not  conclusive  [176,  178-183].  While  a
positive correlation between CPE scores and neurological outcomes are observed in sever‐
al studies, one study revealed that ART regimens with higher CPE scores might be associ‐
ated with worse neurocognitive performance [184].
These studies investigating the effect of CPE scores on neurological outcomes have inherent
caveats. First, due to the limited methodologies, the clinical studies cannot assess the drug
concentrations in the brain parenchyma, and instead depend on the CSF levels, which are
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usually based on measurements after a single-dose administration of the drug. Several fac‐
tors, such as poor drug adherence and the impact of co-prescribed drugs on the pharmaco‐
kinetics of antiretroviral drugs can impact the CNS concentrations and can confound the
measured outcomes.Additionally, the escape of drug-resistant viral species into the CNS
and their establishment in viral reservoirs early during infection can lead to the rise of drug-
resistant HIV species in the CNS, and can hinder the efforts to assess the impact of CPE
scores on neurological outcomes. Further, co-morbidity factors impacting the integrity of the
BBB should also be considered in assessing drug availability in the CNS. Among these fac‐
tors are cancer, infections, and drug and alcohol abuse, all of which are shown to alter BBB
integrity independent of HIV infection, and should be considered when CPE scores are es‐
tablished and evaluated [185-187]. One final factor to consider in evaluating the long-term
effectiveness of ART is the potential direct toxicities of antiretroviral drugs in the CNS, espe‐
cially given the interest in implementation of ART regimens with better CNS penetrance
and possibly developing nanoART as part of treatment plans. Antiretroviral drugs have
known side-effects in the periphery, including dyslipidemia, and lipohypertrophy. Further,
antiretroviral drug-associated toxicity is well documented in the peripheral nervous system,
and potential CNS toxicities secondary to ART exist. Oxidative damage elicited by antiretro‐
viral drugs is of particular interest, given ample evidence of ongoing oxidative stress in the
HAND brain, as described above.
In several cavalier studies, researchers eloquently demonstrated in several cell populations
(human adipocytes, monocytes, myeloid cell lines, and human aortic endothelial cells) that a
variety of drugs from the PI and NRTI families, alone or in combinations, induced the pro‐
duction of ROS, hydrogen peroxide, and factors promoting monocyte recruitment. The com‐
pounds reported to induce these changes included PIs: indinavir, nelfinavir, lopinavir,
ritonavir, saquinavir, atazanavir and NRTIs: stavudine (d4T), zidovudine (AZT), and dida‐
nosine [97-99, 188-191]. The compounds amprenavir (PI) and abacavir (NRTI) were consis‐
tently reported as lacking these effects, making these drugs good candidates for inclusion in
regimens to be prescribed to patients with HAND [98].
As the first available antiretroviral drug, AZT has been extensively studied. While AZT may
not be a mainstay drug of choice for customized optimal regimens, as the primary ART
compound available in resource-limited developing countries, it is still of importance to un‐
derstand its cellular effects. AZT was approved for treatment in 1987, and as early as 1992
the Papoian laboratory reported deficits in mitochondrial enzymes and uncoupling of the
electron transport chain (ETC) [192]. The disruption of the ETC is a primary cause of mito‐
chondrial based intracellular ROS accumulation and mitochondrial DNA oxidation, an ef‐
fect since expounded upon in multiple laboratories after acute AZT exposure in isolated
heart mitochondria and primary human cardiomyocytes, and after chronic gestational AZT
exposure in mouse liver and kidney and in the lung and brain of fetal patas monkeys
[193-196]. This compound has also been shown to increase mitochondrial lipid peroxidation,
deplete intracellular glutathione, and lead to oxidation of remaining glutathione, ultimately
inducing a caspase-3- and caspase-7- dependent apoptotic death [193, 195, 197]. When an‐
other NRTI, d4T was investigated, it also was shown to produce ROS, mitochondrial oxida‐
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tive stress, oxidized mitochondrial DNA, and altered activity of mitochondrial oxidative
phosphorylation enzymes [198, 199]. Similarly, NRTI zalcitabine (ddC) also induces oxida‐
tive stress, as evidenced by the accumulation of protein carbonyls and nitrotyrosine modifi‐
cations. Interestingly, this study also reported that the better-tolerated cytidine analog
lamivudine (3TC) did not produce these effects, suggesting that 3TC may be considered as
an alternative to reduce oxidative stress, and that future compounds generated from this
structural base may behave similarly [200]. Interestingly, in contrast to studies in human
lymphoid cells, Brandmann and collegues have recently reported that in astrocytes AZT,
lamivudine, efavirenz, and nevirapine do not appear to reduce intracellular levels of gluta‐
thione [190]. Whether or not these compounds behave similarly in neurons and other cell
populations in the CNS remains to be elucidated.
In the non-nucleoside reverse transcriptase inhibitor (nNRTI) drug class, efavirenz applied
to a human hepatoblastoma cell line resulted in superoxide generation, depletion of intracel‐
lular glutathione, and decrease in mitochondrial function and membrane potential that was
independent of mitochondrial DNA replication [201]. In addition, efavirenz has also been
linked to neuropsychological side effects in HIV-infected patients, and it is probable that the
specific oxidative stress effects on mitochondria and glutathione may play a role in the neu‐
rotoxicity of this compound, as neurons are particularly sensitive to perturbations in the an‐
tioxidant system [201, 202].
Within the protease inhibitor class, both ritonavir and amprenavir have been associated
with increased superoxide anion production, while ritonavir has been shown to cause in‐
creases in nitrotyrosine levels in porcine coronary arteries [203]. On the other hand, both in‐
dinavir and nelfinavir have been shown to induce a time and concentration dependent
depletion of intracellular glutathione in astrocytes as well as in pancreatic beta cells [99,
190]. Nelfinavir is of particular interest, as it suppresses cytosolic, rather than mitochondrial
superoxide dismutase levels, and induces a necrotic rather than apoptotic cell death cascade
in an adipocyte cell line [99, 204]. Future studies of this compound will undoubtedly prove
interesting and may have important implications in patients with regard to their neurocog‐
nitive outcomes associated with this compund. Finally, it is interesting to note that multiple
studies investigating the oxidative effects of the thymidine analogs in the NRTI class have
reported increased ROS, hydrogen peroxide, and nitric oxide intermediates but no superox‐
ide anions [188, 205].
Currently, there is no information on possible oxidative effects of the entry inhibitor, inte‐
grase inhibitor, and mutation inhibitor drug classes. Similarly, the lack of published studies
for the neuroglial cell populations in the brains of HAND patients is surprising. Several
posters at national and international meetings over recent years have addressed this impor‐
tant issue, and hopefully these reports will be forthcoming [206, 207]. In order to design cus‐
tom drug regimens which will not precipitate, or can ameloirate oxidative stress, cellular
dysfunction and death, it is critical to have an understanding of the cellular effects of each
currently approved antiretroviral compound, and to design future compounds with mini‐
mal oxidative effects. Further, it is possible that the continued dysfunction in superoxide
production and superoxide dismutase levels in patients may be due to the effects of more
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than one drug in a multi-drug regimen. Thus, designing future combinations which do not
precipiateoxidative stressis of utmost importance in efforts to resolve the persistence of
HAND observed in the ART era.
4.4. Potential therapeutic avenues for oxidative stress in ART era
Since the manifestations of oxidative stress induced by HIV and ART have emerged, it has
also become evident to scientists that boosting the endogenous antioxidant response may be
a valid and encouraging adjunctive therapeutic option. Within the cell, the antioxidant re‐
sponse is mediated through the activation of transcription factor NF-E2 (nuclear factor (er‐
ythroid-derived 2)-related factor-2 (Nrf2)and its myriad of effector phase II and III
detoxifying enzymes. Relevant to the previously discussed aberrations in oxidant detoxifica‐
tion, this pathway upregulates superoxide dismutase, peroxiredoxins, thioredoxins, and
multiple glutathione biosynthesis enzymes [208, 209].
In vitro, multiple compounds which act upon the Nrf2 pathway have proven effective in
ameliorating the oxidative effects of viral infection, viral proteins or antiretroviral drugs.
Among these compounds are resveratrol, dimethyl fumarate, N-acetylcysteine, and curcur‐
min [189, 191, 193, 203, 210]. Antioxidants which have not yet been shown to act through the
Nrf2 pathway, but which have similar effects in vitro include dihydroxybenzyl alcohol, wa‐
ter soluble vitamin E (trolox), glutathione mimetic tricyclodecan-9-yl-xanthogenat, and ace‐
tyl-l-carnitine [188, 200, 201, 211]. An alternative approach to specifically inhibit the actions
of NADPH oxidase through the compound diphenyleneiodonium, was able to specifically
prevent the effects of PIs, but not NRTIs in human adipocytes [98]. This interesting finding
suggests that the different antiretroviral classes may lead to ROS production through differ‐
ent mechanisms, and that specific therapeutics targeting individual oxidant-producing en‐
zymes or pathways may need to be considered for specific ART regimens.
An alternative approach to activating Nrf2 pathway is supplementation with the antioxi‐
dant vitamin C (ascorbate), which is capable of directly scavenging reactive oxygen and ni‐
trogen species. This method has been shown to be effective in counteracting the deleterious
effects of gp120, as well as nelfinavir in vitro, and has been shown to have beneficial out‐
comes in patients, when supplemented to ART regimens [100, 195, 204]. Along these same
lines, supplementation with a variety of other antioxidants and micronutrients including
minocycline, glutathione replenishing peptide alpha-lipoic acid, selenium, vitamin A, Vita‐
min E, and a multivitamin regimen including vitamins A, C, E selenium and coenzyme Q10
have demonstrated partial protection from the deleterious oxidative effects of HIV/SIV and
ART in vivo, with particular emphasis on restoration of the total blood glutathione levels
[127, 195, 212-214]. Finally, the NMDA-receptor blocker memantine, and monoamide oxi‐
dase type B inhibitor selegiline, approved for treatment in Alzheimer and Parkinson Diseas‐
es, respectively, have also been proposed as potential therapeutics for HAND [1, 214].
Memantine might exert therapeutic effects through reduction of residual virus-mediated
glutamate excitotoxicity, and selegiline has been reported to be capable of reducing oxygen-
based free radicals [215, 216]. The use of these compounds and their efficacy in reducing oxi‐
dative damage in HAND are still in early stages. Initial studies were confounded by the fact
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that much damage was already present in late stage HAD patients and a protective effect at
this stage was not evident [217]. Further work with these compounds will require identify‐
ing patients with ANI or MND to enroll in longitudinal studies to determine whether these
compounds will have long-term benefit.
Going forward, it is imperative that the oxidative stress imposed by HIV and ART are tar‐
geted by adjunctive therapies. As research progresses with the quest for eliminating viral
reservoirs and designing more effective, less toxic antiretroviral compounds, it is important
to keep in mind that oxidative stress is and will continue to be a persistent burden, especial‐
ly in a patient population with a significantly enhanced life expectancy.
5. The impact of co-morbidities on HAND
HIV, once an acute and catastrophic infection, has now become a chronic and manageable
disease, with advances made in diagnosis and treatment. These changes are reflected in the
increases in life expectancy from 5 years to up to the projected 50 years from the time of di‐
agnosis. However, with the increased lifespan, co-morbidities, such as chronic co-infections,
substance abuse, and aging have become major contributors to HAND persistence, and need
to be addressed for successful evaluation and treatment of HAND.
The compromised immune system in an HIV-infected individual increases the risk of op‐
portunistic infections in the CNS, much like that observed in the peripheral tissue. Most
commonly observed infections, CNS toxoplasmosis, cryptococcosis, CNS tuberculosis, and
cytomegalovirus encephalitis can be treated successfully by a combination of antimicrobi‐
als,  antiviral and antiretroviral drugs. However,  there are several other viral agents that
can either directly target or indirectly compromise CNS, and cannot be readily managed
by antiretroviral drugs or chemotherapeutics. One important virus with serious complica‐
tions in HAND patients is JC virus, the causative agent of progressive multifocal leukoen‐
cephelopathy (PML). While approximately 60-80% of adults globally are seropositive for
JC virus, it leads to the development of PML mostly in individuals who are immuno-com‐
promised,  either  due to an underlying cancer or  immunosuppressive treatment,  or  who
are  HIV-positive.  The  current  incidence  of  PML  in  HIV  patients  is  3%.  Studies  have
shown that JC virus can traffic across the BBB within the B cells, can enter the CNS as a
free virus, or can infect brain vascular endothelial cells. Once in the CNS, JC virus causes
the lytic infection of oligodendrocytes, and results in multifocal demyelination in multiple
regions  of  the  white  matter.  Thus,  PML may exacerbate  white  matter  loss  that  may al‐
ready be occurring in HAND patients. Further, the most efficient, however limited, treat‐
ment  for  PML,  which is  immune restoration with  aggressive  antiretroviral  therapy,  can
potentiate immune reconstitution inflammatory syndrome (IRIS).  IRIS,  a  T-cell  mediated
encephalitis,  can  precipitate  further  injury  and  worsening  of  neurological  symptoms.
While fatality due to PML in HIV-infected individuals can be as high as 50%, the number
of cases with non-lethal  PML is  increasing and PML may be contributing to the persis‐
tence of HIV-associated neurological complications.
Current Perspectives in HIV Infection178
Hepatitis B and C (HBV and HCV) are also commonly found in HIV-infected individuals
due to the shared risk factors of contracting the virus. While these viruses are not thought to
target the primary cells of the CNS, a recent study has reported the presence of HCV anti‐
gens in astrocytes and the cells of the macrophage/microglial lineage in the human brain.
Additionally, there is limited evidence suggesting that HCV core protein might be detrimen‐
tal to neurons in vitro and in vivo. Further, several studies have suggested that HCV and HIV
can potentiate each other’s replication. Currently, there is no conclusive data regarding a
possible correlation between HCV presence in the CNS and the neurocognitive deficits in
HAND patients. However, the potential implications of HCV infection in the CNS are at
least three-fold. First, HCV co-infection can hinder the efforts to suppress HIV replication in
the CNS. Second, weakened immune system function secondary to HCV will negatively im‐
pact subsequent alleviation of neurocognitive functions. Finally, compromised functioning
of CNS support cells, mainly astrocytes, secondary to concomitant HCV infection will aug‐
ment the neuroinflammatory environment with a negative impact on neuronal health. These
implications may underlie the evidence that suggests that viral suppression and CD4+ cell
recovery is not as successful in the presence of HCV, and might partially explain the spora‐
dic data suggesting that worse neurocognitive impairment is observed in HIV-HCV co-in‐
fected patients [184].
Illicit drug use, as well as alcohol abuse, put HIV-positive patients at a greater risk for
HAND [6, 218-224]. The prevalence of HIV infection is 11-17% among illicit drug users, and
methamphetamine (METH) is among the most frequently abused drug with well-known
toxic effects on the BBB and in the CNS [220]. HIV-infected patients using METH exhibit
more neurocognitive deficits, compared to those not using METH. These findings are likely
due to the effects of METH on several fronts in the CNS. First, extensive studies have con‐
clusively shown that METH alters the BBB permeability through direct damage to the
BMECs, which in turn can augment HIV access to the CNS. Additionally, METH can exert
neurotoxic effects in the CNS through oxidative stress and mitochondrial dysfunction [184],
and precipitate further synaptic and neuronal damage. METH may also interfere with the
expected benefits of ART in several ways. Most importantly, studies have shown that al‐
tered patient behavior due to METH use can interfere with drug adherence. Secondly, al‐
tered BBB function in a patient using METH can potentially alter antiretroviral access to the
CNS, hindering efforts to establish an efficient regimen with limited side effects.
6. Aging and HAND
The widespread use of ART has drastically decreased the incidence of AIDS-related compli‐
cations and improved the long-term prognosis of HIV-positive individuals. Currently, 30%
of the HIV-positive population in the United States is over the age of 50,and by 2015 it is
estimated that more than 50% will be over the age of 50 [225, 226]. Despite this remarkable
development, the life expectancy for ART-treated HIV-positive individuals remains 10-30
years less than that of uninfected individuals [227]. Given the rapid global expansion of this
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population, it has become increasingly important to understand the risk factors that lie at
the intersection of HIV, ART, and aging.
Older HIV-positive patients,  including those treated with ART, are at  increased risk for
systemic diseases including atherosclerosis, liver and kidney failure, cancer, and osteopo‐
rosis [227, 228]. The aging brain may also be more vulnerable to the effects of HIV as old‐
er adults display an increased susceptibility to HAND, and emerging evidence suggests
an increased prevalence of neurodegenerative diseases, including Alzheimer and Parkin‐
son, in this patient population [229, 230]. It remains unclear if the increased prevalence of
HAND is a result of HIV and related comorbidities, including hypertension, insulin resist‐
ance,  and  lipodystrophy,  or  other  confounding  factors  such  as  immunosenescence  and
ART toxicities,  all  of  which are likely to impact  CNS disease progression in older HIV-
positive individuals [231, 232].
Antiretroviral therapy effectively limits HIV disease progression, maintains patients in a
state of partial immune competence, and arrests subjects in a pre-symptomatic state [233].
However, despite the ability of ART to reduce plasma HIV RNA to undetectable levels,
HIV-positive individuals remain at higher risk for opportunistic illnesses and premature
death [234, 235]. Thus, ART may reduce, but does not appear to eliminate, premature and/or
accelerated aging in HIV-infected individuals. This may be attributed to many factors in‐
cluding drug toxicity and slower immune recovery following ART initiation in older pa‐
tients, compared to younger adults [236]. Furthermore, advanced age has been linked to
decreased production of T cells, B cells, and cytokines as well as to chronic immune activa‐
tion, the latter of which may be linked to the breakdown of gut-associated lymphoid tissue
(GALT) and to the elevated levels of systemic lipopolysaccharide (LPS) [237, 238].
Older patients also display a dampened recovery of CD4 cells following treatment with
ART, which may increase their risk for systemic diseases ranging from heart disease to can‐
cer [238]. Thus, it is not surprising that advanced age at seroconversion and/or onset of ART
treatment is considered a major risk factor for severe HIV disease [239, 240]. Goetz, et al.
performed a retrospective study on HIV-positive patients receiving ART treatment at the
Veteran’s Administration Greater Los Angeles Medical center between 1996 and 1999, and
found that for every 10 years of additional age at the onset of ART treatment, the rate of
CD4 cell replenishment decreased by 35 cells per microliter of blood [241]. Yet, despite the
obvious benefits of beginning ART treatment in asymptomatic HIV-positive individuals,
there remain significant concerns for initiating drug therapy sooner than necessary and how
this may negatively impact drug toxicity, long-term patient outcome, and the evolution of
drug resistant strains of HIV [240, 242]. Based on the updated recommendations for treat‐
ment initiation, as mentioned previously, all HIV-infected individuals will be put on ART
regimen upon diagnosis, and the impact of this approach on older patients will be revealing.
Lower CD4 count, in addition to advanced age, also places older patients at a nearly four-
fold higher risk for liver-related mortality compared to younger patients [243]. This risk is
exacerbated by other factors commonly afflicting ART-treated, HIV-positive individuals in‐
cluding diabetes, alcohol abuse, as well as antiretroviral and cholesterol drug toxicity [243].
Among all non-AIDS-related complications, liver disease is the primary cause of death in
Current Perspectives in HIV Infection180
HIV-positive patients [243]. In addition, older HIV-positive individuals are at increased risk
for frailty, bone loss and non-AIDS related cancers [244, 245]. It remains unclear if HIV itself
places older individuals at higher risk for heart disease compared to older, HIV-negative in‐
dividuals, though specific classes of antiretrovirals, especially protease inhibitors, have been
linked to atherosclerosis [237, 246, 247].
The CNS is particularly susceptible to the synergistic neurodegenerative effects of HIV and
aging. Several studies have demonstrated that, compared to younger (age 20 to 39 years) co‐
horts, older HIV-positive individuals (age > 50 years) display decreased neurocognitive
functioning in several areas including memory, psychomotor speed, and executive functions
[225, 248, 249]. The persistence of HAND in individuals with an undetectable viral load and
CD4 cell counts greater than 200/μL is not well understood and may be a result of aging-
associated processes rendering the cells of the CNS more vulnerable.
Several recent neuroimaging studies have begun to address the structural, physiological,
and functional changes in the CNS in the context of HIV and aging. Six MRI investigations
that assessed the structural changes in the brains of older HIV-positive individuals between
1998 and 2012 found evidence of premature or accelerated aging characterized by significant
brain atrophy in the basal ganglia, cerebellum, and frontal and temporal brain regions,
when compared to seronegative controls [231]. However, several diffusion tensor imaging
(DTI) studies found only normal, age-dependent changes in mean diffusion and fractional
anisotropy, which reflects the directionality of water diffusion in the brain, and is greater
along organized white matter tracts but decreased in pathologically damaged, disorganized
tracts [231, 250-252].
Other studies have employed proton magnetic resonance spectroscopy (MRS) to assess the
changes in brain metabolite levels that are indicative of neuronal damage and death or glial
activation. Ernst and Chang demonstrated a five-fold acceleration of aging effects in a rela‐
tively young (mean age 36 years) ART-naïve, HIV-positive cohort, as compared to HIV-neg‐
ative controls, as reflected by increased levels of glial activation markers, myoinositol (MI)
and choline compounds (CHO), and a decrease in the neuronal marker, N-acetylaspartate
(NAA) [253]. A recent multicenter MRS study of slightly older (ages 30-70], ART-treated
HIV-positive individuals demonstrated elevated MI and CHO in all brain regions of pa‐
tients with asymptomatic or mild neurocognitive impairment, but decreased levels of MI in
those with dementia, which the authors interpreted as premature microglial senescence
[231, 254]. In addition, this study found an age-dependent decrease in NAA in frontal white
matter, but only in patients with HAD [254]. Thus, while ART-naïve HIV-positive patients
show evidence of increased, age-dependent glial activation and neuronal damage leading to
accelerated aging, ART-treated individuals show only signs of premature aging [231].
As mentioned previously, the clinical and pathological hallmarks of post-ART HAND differ
from those in the pre-ART era. While HAD presented as a subcortical dementia afflicting the
basal ganglia and white matter, some post-ART studies suggest the focus of neuroinflamma‐
tion has shifted primarily to the hippocampus, even in effectively treated patients [255-257].
Furthermore, there is emerging evidence that pathologic similarities exist between HAND
and some common neurodegenerative disorders such as Alzheimer Disease, which is char‐
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acterized by the presence of extracellular beta amyloid (Aβ) plaque deposits, and intracellu‐
lar neurofibrillary tangles composed of hyperphosphorylated Tau [228, 233, 258, 259]. In
vitro work involving the viral protein Tat has demonstrated the ability of this viral protein to
inhibit the activity of the Aβ-degrading enzyme, Neprilysin, and the ability to bind to the
receptor for advanced glycation end products, all of which may promote Aβ accumulation
in the CNS. Indeed, some individuals with HAND display CSF levels of Aβ42 comparable
to those observed in AD patients [228, 260, 261]. However, a recent report utilizing the amy‐
loid-binding, carbon 11-labeled Pittsburgh compound B (11C-PiB) and PET imaging found
that irrespective of neurocognitive impairment, HIV-positive individuals showed no in‐
crease in 11C-PiB levels, highlighting a potential key difference between Aβ metabolism in
HAND vs. AD despite some overlapping pathological features [258].
Among the studies underlining the similarities between HAND and AD, Esiri et al. were the
first to report a predisposition to plaque formation in the brains of pre-ART HIV-positive
individuals [262]. Such pathological changes have been observed in HIV-positive patients
despite successful virologic control with ART, suggesting that antiretrovirals either cannot
achieve therapeutic concentrations within the brain parenchyma, allowing for ongoing viral
replication and neuroinflammation, or may have toxic effects that could facilitate neurode‐
generation [263, 264]. To address the latter concern, several reports investigated differences
in either phospho-tau or beta amyloid levels in ART-naïve vs. ART-treated individuals. Two
groups independently reported elevated Aβ deposition in the hippocampus of ART-treated
individuals compared to pre-ART patients, yet Anthony et al. reported only increased hy‐
perphosphorylated tau, but no Aβ deposition in the hippocampus and entorhinal cortex of
HIV-positive individuals [257, 259, 265]. To date, no group has reported concomitant phos‐
pho-tau and Aβ plaque depositions in the same brain samples from HIV-positive cohorts.
Differences in patient age and ART-regimens, as well as the antibodies used to detect Aβ
may account for the varied outcomes of these reports.
Importantly, the aforementioned studies highlight the potentially under-appreciated con‐
cern of antiretroviral-associated toxicity and its effect on neuropsychological outcomes in
long-term  ART-treated  patients.  As  described  earlier,  ART  drugs  have  been  linked  to
wide-ranging,  peripheral  metabolic and neural  disturbances that could themselves influ‐
ence the progression of HAND and foretell potential mechanisms of toxicity in the CNS
[246, 266-276]. While CNS effects of ART are poorly understood, Schweinsburg et al. dem‐
onstrated  an  association  between  NRTIs  and  decreased  levels  of  frontal  white  matter
NAA, which they attributed to NRTI-mediated mitochondrial dysfunction and depletion
of cellular respiration [268]. Confounding the issue of direct CNS toxicity of antiretroviral
medications is the variability in BBB permeability amongst different drug classes as deter‐
mined by various physicochemical properties such as plasma protein binding, lipophilici‐
ty, and molecular size.
Although it  is  a  widely held that  ART regimens with higher  CNS penetrance generally
confer greater neuropsychological outcomes in HIV-positive individuals,  numerous clini‐
cal  studies  have  suggested  these  regimens  may  negatively  impact  cognition.  In  a  pro‐
spective  study,  Marra  et  al.  found  a  significant  association  between  highly  CNS-
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penetrant  ART  regimens  and  worse  neurocognitive  and  motor  performance,  despite
decreased CSF HIV RNA in a small HIV-positive cohort [181].  In addition, Robertson et
al. reported an improvement in neuropsychological outcome in a cohort of patients with
interrupted  drug  treatment  [277].  Studies  using  SCID  mice,  which  display  neuropatho‐
logical  hallmarks  similar  to  those  associated  with  HIV,  showed reduced viral  load and
astrogliosis  following administration of  ART, but no improvement in cognitive dysfunc‐
tion [278].  Altogether,  these  studies  reinforce  an emerging hypothesis  that  antiretroviral
drugs may be contributing to the rising prevalence of HAND in the aging HIV-positive
population.
However,  many  clinical  studies  have  demonstrated  beneficial  effects  on  neurocognitive
functioning by ART regimens with high CPE scores [279, 280]. A cross-sectional study of
2636 adults  from the  AIDS Clinical  Trials  Group Longitudinal  Linked Randomized Tri‐
als (ALLRT cohort),  on effective ART for at  least 6 weeks showed better neurocognitive
performance in individuals  receiving ART medications with higher CPE scores [281].  In
some  cases,  participants  required  more  than  3  antiretrovirals  to  treat  HIV  in  the  CNS.
Letendre  et  al.  demonstrated  improvements  in  cognition  over  a  15-week  period  in  pa‐
tients beginning ART with higher CPE ART regimens [282]. Another recent investigation
utilized MRS imaging to investigate the effect  of  different  CPE ART regimens with dif‐
ferent CPE scores on changes in brain NAA metabolite levels. Over 48 weeks, HIV-posi‐
tive,  ART-naïve  individuals  receiving  the  regimens  with  highest  CPE  scores  displayed
the highest increases in NAA levels,  and showed the greatest improvement in a battery
of neuropsychological tests [283]. These studies suggest that ART medications with high‐
er  CNS penetrance  may have  a  neuroprotective  effect  in  successfully  treated  HIV-posi‐
tive  adults.  However,  given  the  well-characterized  toxicities  of  ART medications  in  the
periphery,  and the potential  impact of  related co-morbidities on CNS pathology,  it  may
be necessary to consider adjunctive therapies to minimize the synergistic  effects of  ART
and aging in HIV-positive individuals.
7. Summary
The advent of ART has profoundly changed the landscape of disease; however, neurocogni‐
tive impairments continue to be debilitating to patients with the expected life expectancy
closer to that of the uninfected population. A better understanding and appreciation of the
confounding factors has become more acute as the recent focus in the race to cure AIDS has
shifted towards the eradication of latent viral reservoirs, including those in the CNS. It is im‐
perative to anticipate and control the immune responses due to viral reactivation, the poten‐
tial neurotoxicities of viral proteins in the brain parenchyma when latent viral progeny is
activated, and the oxidative damage that may be precipitated by viral particles and the acti‐
vated immune cells. These factors will be even more crucial to control in the aging brain
with limited cognitive reserves.
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